Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned an average recommendation of “Hold” from the eight research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $4.94.

Several research analysts recently issued reports on IRWD shares. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $1.92 on Tuesday. The firm has a market capitalization of $311.87 million, a price-to-earnings ratio of -38.39 and a beta of 0.30. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.13. The company has a 50-day moving average of $1.42 and a 200 day moving average of $1.00.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently modified their holdings of IRWD. Vanguard Personalized Indexing Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 43.5% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 22,029 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Ironwood Pharmaceuticals by 23.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock worth $202,000 after buying an additional 28,928 shares in the last quarter. SG Americas Securities LLC bought a new position in Ironwood Pharmaceuticals in the third quarter worth approximately $48,000. Merit Financial Group LLC lifted its holdings in Ironwood Pharmaceuticals by 17.4% during the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock worth $64,000 after buying an additional 7,232 shares during the period. Finally, CWM LLC boosted its position in Ironwood Pharmaceuticals by 27.4% during the 3rd quarter. CWM LLC now owns 232,790 shares of the biotechnology company’s stock valued at $305,000 after acquiring an additional 50,016 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.